Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(1):4-5; doi:10.1093/jnci/djj023
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McLaughlin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLaughlin, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

EDITORIAL

Stats on Statins: Anything but Static

John McLaughlin

Correspondence to: John McLaughlin, PhD, Preventive Oncology, Cancer Care Ontario and Prosserman Centre for Health Research, 620 University Ave., Toronto, Ontario M5G 2L7, Canada (e-mail: john.mclaughlin@cancercare.on.ca).

The first 10% of the full text of this article appears below.

The short report on a large cohort study by Jacobs et al. (1) in this issue of the Journal contributes substantially to the growing body of evidence on whether statins have chemopreventive effects and lead to reduced colorectal cancer risk. The search for effective chemoprophylaxis is an important quest that is motivated in part by the potential benefits that could be achieved by preventing colorectal cancer and by the early promise of agents, such as aspirin, other nonsteroidal anti-inflammatory agents, and cyclooxygenase . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?